Description: Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Home Page: www.inventivapharma.com
50 rue de Dijon
Daix,
21121
France
Phone:
33 3 80 44 75 00
Officers
| Name | Title |
|---|---|
| Mr. Frederic Cren | Co-Founder, CEO & Chairman |
| Dr. Pierre Broqua Ph.D. | Co-Founder, Chief Scientific Officer, Deputy CEO & Director |
| Mr. Jean Volatier | Chief Financial Officer |
| Mr. Eric Duranson L.L.M. | Gen. Counsel |
| Ms. Nathalie Harroy | Head of HR |
| Dr. Irena Konstantinova | Head of Biology & Pharmacology |
| Dr. Michael Cooreman | Chief Medical Officer |
| Mr. Jean-Paul Dutertre M.D. | Head of Pharmacovigilance |
Exchange: PA
Country: FR : France
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.4685 |
| Price-to-Sales TTM: | 17.6622 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 109 |